Long-term migraine tablet study for kids and teens ages 6–17
Treatments studied
Part of Brain & nervous system clinical trials.
This study follows kids and teens who already took part in an earlier migraine medication study to check long-term safety and comfort with oral ubrogepant tablets. It may help families understand whether this migraine tablet is safe to keep using over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished an earlier ubrogepant migraine study (or you may qualify if you joined but were not in the main treatment because you responded to placebo).
- You must have followed study steps well in the earlier study and not had an event that raised safety concerns, according to the study doctor.
- You must be able to stop or switch any “not allowed” medicines or diet items by the first study visit (for example, certain medicines or grapefruit products).
- Your first-visit health checks (heart tracing and physical exam) must not show serious problems.
- You must not be at significant risk of self-harm or harming others based on an interview and questionnaire at the first visit.
- You must be able to attend study visits and follow the study plan (including staying in the area during the study), as judged by the study doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how safe ubrogepant is and whether it helps treat an individual migraine attack in children and teens. It focuses on measuring side effects and whether headaches improve 2 hours after taking the study medicine.
This study looks at ways to help children and teens with migraine headaches by testing a care approach that includes access to evidence-based treatment. It may help if your child has frequent migraine headaches and is starting (or not already on) certain migraine-preventive medicines.
This study looks at how well the migraine medication ubrogepant works when taken during the early signs of a migraine (prodrome). It may help people who already use ubrogepant for their migraines.
This trial studies whether rimegepant can reduce how often migraine attacks happen in children and teens. It also looks at safety and how well the treatment fits day-to-day life and school activities.
This trial studies eptinezumab, a migraine treatment, in children and teens ages 6 to 17 who already completed an earlier migraine study. It mainly helps doctors learn whether the treatment can be continued safely and effectively over time.
This study tests if atogepant, a daily pill, can prevent migraines in adults. It is for people whose doctor has already decided to prescribe atogepant for migraine prevention.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.